RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
ADMA Biologics Stock

ADMA Biologics P/E 2024

ADMA Biologics P/E

18.86

Ticker

ADMA

ISIN

US0008991046

WKN

A12FAG

As of Oct 4, 2024, ADMA Biologics's P/E ratio was 18.86, a -159.29% change from the -31.81 P/E ratio recorded in the previous year.

The ADMA Biologics P/E history

ADMA Biologics Aktienanalyse

What does ADMA Biologics do?

ADMA Biologics is a leading company in the development and manufacturing of biological therapies for the treatment of serious diseases. The company was founded in 2004 and is headquartered in Ramsey, New Jersey. ADMA Biologics' business model is based on the development and manufacturing of specialized biological therapies tailored to the needs of patients with rare diseases and severe infections. It specializes in the development of plasma-based therapies to treat patients with immune deficiency and autoimmune diseases, hemophilia, and severe blood loss due to trauma or surgery. ADMA Biologics' products include intravenously administered immune globulin (IVIG) called BIVIGAM, approved for intravenous infusion in patients with primary immune deficiency or other immune disorders. CyclASol, an eye drop for patients with the eye inflammation Keratoconjunctivitis Sicca, is also a product developed by ADMA Biologics. Additionally, ADMA Biologics is currently expanding its product portfolio through the development of PDIG, a product in phase III clinical trial for the treatment of secondary immune deficiencies. The company has long-standing partnerships with other companies and organizations in the industry to combine its resources and expertise in the development and marketing of innovative therapies. ADMA Biologics also operates its own plasma collection center to ensure the supply of plasma for its therapies. In terms of its divisions, ADMA Biologics currently focuses on the USA, where the company offers its products through a dedicated sales team. Additionally, ADMA Biologics aims to expand its presence worldwide by introducing its products into new regions and markets. The company has achieved important regulatory milestones in Europe and other parts of the world, including the approval of BIVIGAM's sale in Korea and the Industrial Ministry Jubilee Memorial for BIVIGAM's introduction in Japan. ADMA Biologics' history began in 2004 when the company specialized in the development and manufacturing of plasma-based therapies for patients with rare diseases. In 2009, the company received its first FDA approval for ASCENIV, an immune globulin product for the treatment of immune deficiency disorders. In 2011, ADMA Biologics acquired a plasma collection center to expand its resources and capabilities and ensure an independent supply chain for plasma. Since then, the company has gained importance in the industry through the development and introduction of innovative products and therapies. In 2018, ADMA Biologics established a subsidiary in Germany to support the company's expansion into the European continent. In the same year, the company also obtained FDA approval in the United States for BIVIGAM, the first IVIG product manufactured from human plasma in the country. Overall, ADMA Biologics has a strong brand presence in the industry and is successfully expanding its portfolio of plasma-based therapies. The company has established strong partnerships with organizations in the industry to jointly develop and bring innovative solutions to a wide range of diseases. ADMA Biologics has a very positive future outlook and is expected to play a significant role in the field of biological therapies by continuing to develop and bring innovative therapies to the market. ADMA Biologics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering ADMA Biologics's P/E Ratio

The Price to Earnings (P/E) Ratio of ADMA Biologics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing ADMA Biologics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of ADMA Biologics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in ADMA Biologics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about ADMA Biologics stock

What is the price-to-earnings ratio of ADMA Biologics?

The price-earnings ratio of ADMA Biologics is currently 18.86.

How has the price-earnings ratio of ADMA Biologics changed compared to last year?

The price-to-earnings ratio of ADMA Biologics has increased by -159.29% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of ADMA Biologics high compared to other companies?

Yes, the price-to-earnings ratio of ADMA Biologics is high compared to other companies.

How does an increase in the price-earnings ratio of ADMA Biologics affect the company?

An increase in the price-earnings ratio of ADMA Biologics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of ADMA Biologics affect the company?

A decrease in the price-earnings ratio of ADMA Biologics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of ADMA Biologics?

Some factors that influence the price-earnings ratio of ADMA Biologics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does ADMA Biologics pay?

Over the past 12 months, ADMA Biologics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ADMA Biologics is expected to pay a dividend of 0 USD.

What is the dividend yield of ADMA Biologics?

The current dividend yield of ADMA Biologics is .

When does ADMA Biologics pay dividends?

ADMA Biologics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ADMA Biologics?

ADMA Biologics paid dividends every year for the past 0 years.

What is the dividend of ADMA Biologics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ADMA Biologics located?

ADMA Biologics is assigned to the 'Health' sector.

Wann musste ich die Aktien von ADMA Biologics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ADMA Biologics from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did ADMA Biologics pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of ADMA Biologics in the year 2023?

In the year 2023, ADMA Biologics distributed 0 USD as dividends.

In which currency does ADMA Biologics pay out the dividend?

The dividends of ADMA Biologics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von ADMA Biologics

Our stock analysis for ADMA Biologics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ADMA Biologics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.